Tesla, EEOC Move Toward Mediation in Racial Harassment Lawsuit 
BlueScope Steel Announces A$1 Special Dividend After Asset Sales 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
AFT Leaves X Over AI-Generated Images of Minors 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
Amazon Reviews Supplier Costs as U.S.–China Tariffs Ease 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Trump Administration Approves Nvidia H200 AI Chip Sales to China Under New Export Rules 
Saks Global Files for Bankruptcy Protection Amid Mounting Luxury Retail Pressures 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
Alphabet Stock Poised for Growth as Bank of America Sees Strong AI Momentum Into 2026 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
SAN DIEGO, March 29, 2017 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that Charles Theuer, M.D., Ph.D., President and CEO, will present at the 16th Annual Needham Healthcare Conference at 2:20 pm EDT on Wednesday, April 5, 2017, at the Westin Grand Central Hotel in New York, NY.
To access a live webcast of the presentation, please visit the “Events and Presentation” section within the “Investors” section of the TRACON Pharmaceuticals website at www.traconpharma.com. A replay of the webcast will be available on the website for 60 days following the event.
About TRACON
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Company Contact: Casey Logan Chief Business Officer (858) 550‐0780 ext. 236 [email protected] Investor Contact: Andrew McDonald LifeSci Advisors LLC 646-597-6987 [email protected]
